Audentes Therapeutics Inc (NASDAQ:BOLD)’s share price traded up 8.7% during trading on Thursday . The stock traded as high as $38.90 and last traded at $38.53. 1,983,838 shares traded hands during trading, an increase of 203% from the average session volume of 654,943 shares. The stock had previously closed at $35.46.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 11th. Raymond James Financial reissued a “hold” rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. BMO Capital Markets set a $44.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $35.00.

The stock has a market capitalization of $1,112.11, a price-to-earnings ratio of -11.04 and a beta of -0.21.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.88). research analysts expect that Audentes Therapeutics Inc will post -3.5 EPS for the current year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $1,052,480 over the last 90 days. Corporate insiders own 47.30% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its holdings in Audentes Therapeutics by 27.1% during the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 3,324 shares during the period. SG Americas Securities LLC bought a new stake in Audentes Therapeutics during the third quarter valued at about $143,000. Nationwide Fund Advisors boosted its holdings in Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares during the period. Wells Fargo & Company MN boosted its holdings in Audentes Therapeutics by 86.1% during the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 6,667 shares during the period. Finally, Ardsley Advisory Partners boosted its holdings in Audentes Therapeutics by 59.7% during the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 7,500 shares during the period. Institutional investors own 78.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Audentes Therapeutics (BOLD) Trading 8.7% Higher” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/01/25/audentes-therapeutics-bold-trading-8-7-higher.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.